B of A Securities Downgrades Turnstone Biologics to Neutral, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has downgraded Turnstone Biologics from Buy to Neutral and significantly lowered its price target from $10 to $0.5.
October 14, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities downgraded Turnstone Biologics from Buy to Neutral and reduced the price target from $10 to $0.5, indicating a negative outlook.
The downgrade from Buy to Neutral and the drastic reduction in price target from $10 to $0.5 by B of A Securities suggests a negative outlook for Turnstone Biologics. This is likely to lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100